Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Eligible age
Up to 26 yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of AMXT 1501 in combination with DFMO * Test the safety and tolerability of AMXT 1501 in combination with DFMO * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing
Sponsor: Milton S. Hershey Medical Center
You may qualify if…
- ✓ 1. Age:
- ✓ All participants : Must be a maximum of 26 years of age at diagnosis
- ✓ Age at enrollment by Phase:
- ✓ 1. Safety Run-in (Dose level 1)-The first three (3) participants enrolled will be ≥ 12 years of age at enrollment. Once evaluated for safety by DSMB, we will move on to the next three (3) participants enrolled who will be ≥6 years of age at enrollment. Once evaluated for safety by DSMB, we will move on to the Phase I.
- ✓ 2. Phase I and II: ≤ 26 years of age at diagnosis.
- ✓ 2. Pathology
- ✓ All participants must have a confirmed pathologic diagnosis of tumor type (except for DIPG):
- ✓ Relapsed/refractory Neuroblastoma (NB)
You may not qualify if…
- ✕ 1. BSA of \<0.25 m2
- ✕ 2. Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
- ✕ 3. Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible. Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.
- ✕ 4. Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
- ✕ 5. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
Where it's recruiting
Birmingham
Little Rock
Hartford
Gainesville · Miami · Orlando · Tampa
Honolulu
Kansas City
Grand Rapids
St Louis
Hackensack
Hershey
Nashville
Austin · Dallas
Source: ClinicalTrials.gov · NCT06465199 · last updated 2026-11-19